company background image
5392

Syngene InternationalBSE:539268 Stock Report

Market Cap

₹217.6b

7D

-9.5%

1Y

0.5%

Updated

27 Oct, 2021

Data

Company Financials +
539268 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance3/6
Financial Health6/6
Dividends0/6

539268 Overview

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally.

Syngene International Competitors

Divi's Laboratories

NSEI:DIVISLAB

₹1.4t

Dishman Carbogen Amcis

BSE:540701

₹34.0b

Suven Life Sciences

BSE:530239

₹25.4b

Dr. Reddy's Laboratories

BSE:500124

₹772.9b

Price History & Performance

Summary of all time highs, changes and price drops for Syngene International
Historical stock prices
Current Share Price₹548.85
52 Week High₹490.35
52 Week Low₹699.95
Beta0.66
1 Month Change-13.54%
3 Month Change-12.25%
1 Year Change0.49%
3 Year Change91.62%
5 Year Change95.60%
Change since IPO253.64%

Recent News & Updates

Shareholder Returns

539268IN Life SciencesIN Market
7D-9.5%-4.2%-2.3%
1Y0.5%46.8%62.5%

Return vs Industry: 539268 underperformed the Indian Life Sciences industry which returned 46.8% over the past year.

Return vs Market: 539268 underperformed the Indian Market which returned 62.5% over the past year.

Price Volatility

Is 539268's price volatile compared to industry and market?
539268 volatility
539268 Beta0.66
Industry Beta0.36
Market Beta1

Stable Share Price: 539268 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 539268's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19935,437Jonathan Hunthttps://www.syngeneintl.com

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company offers discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also provides exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services.

Syngene International Fundamentals Summary

How do Syngene International's earnings and revenue compare to its market cap?
539268 fundamental statistics
Market Cap₹217.64b
Earnings (TTM)₹4.07b
Revenue (TTM)₹24.48b

53.5x

P/E Ratio

8.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
539268 income statement (TTM)
Revenue₹24.48b
Cost of Revenue₹8.01b
Gross Profit₹16.46b
Expenses₹12.40b
Earnings₹4.07b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)10.26
Gross Margin67.26%
Net Profit Margin16.62%
Debt/Equity Ratio25.7%

How did 539268 perform over the long term?

See historical performance and comparison

Valuation

Is Syngene International undervalued compared to its fair value and its price relative to the market?

53.5x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 539268 (₹548.85) is trading above our estimate of fair value (₹374.87)

Significantly Below Fair Value: 539268 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 539268 is poor value based on its PE Ratio (53.5x) compared to the Indian Life Sciences industry average (21.3x).

PE vs Market: 539268 is poor value based on its PE Ratio (53.5x) compared to the Indian market (21x).


Price to Earnings Growth Ratio

PEG Ratio: 539268 is poor value based on its PEG Ratio (2x)


Price to Book Ratio

PB vs Industry: 539268 is overvalued based on its PB Ratio (7.2x) compared to the IN Life Sciences industry average (3.6x).


Future Growth

How is Syngene International forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

26.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 539268's forecast earnings growth (26.8% per year) is above the savings rate (6.7%).

Earnings vs Market: 539268's earnings (26.8% per year) are forecast to grow faster than the Indian market (19.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 539268's revenue (19.1% per year) is forecast to grow faster than the Indian market (12.6% per year).

High Growth Revenue: 539268's revenue (19.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 539268's Return on Equity is forecast to be low in 3 years time (16.6%).


Past Performance

How has Syngene International performed over the past 5 years?

9.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 539268 has high quality earnings.

Growing Profit Margin: 539268's current net profit margins (16.6%) are lower than last year (17.1%).


Past Earnings Growth Analysis

Earnings Trend: 539268's earnings have grown by 9.2% per year over the past 5 years.

Accelerating Growth: 539268's earnings growth over the past year (14.9%) exceeds its 5-year average (9.2% per year).

Earnings vs Industry: 539268 earnings growth over the past year (14.9%) underperformed the Life Sciences industry 34.7%.


Return on Equity

High ROE: 539268's Return on Equity (13.5%) is considered low.


Financial Health

How is Syngene International's financial position?


Financial Position Analysis

Short Term Liabilities: 539268's short term assets (₹18.8B) exceed its short term liabilities (₹9.4B).

Long Term Liabilities: 539268's short term assets (₹18.8B) exceed its long term liabilities (₹9.1B).


Debt to Equity History and Analysis

Debt Level: 539268's debt to equity ratio (25.7%) is considered satisfactory.

Reducing Debt: 539268's debt to equity ratio has reduced from 77.7% to 25.7% over the past 5 years.

Debt Coverage: 539268's debt is well covered by operating cash flow (85%).

Interest Coverage: 539268 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Syngene International current dividend yield, its reliability and sustainability?

0.19%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 539268's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 539268's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 539268's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 539268's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 539268 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 539268's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Jonathan Hunt (52 yo)

5.75yrs

Tenure

₹65,170,000

Compensation

Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...


CEO Compensation Analysis

Compensation vs Market: Jonathan's total compensation ($USD869.39K) is above average for companies of similar size in the Indian market ($USD588.59K).

Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 539268's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: 539268's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 539268 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Syngene International Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Syngene International Limited
  • Ticker: 539268
  • Exchange: BSE
  • Founded: 1993
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹217.639b
  • Shares outstanding: 396.54m
  • Website: https://www.syngeneintl.com

Number of Employees


Location

  • Syngene International Limited
  • Biocon SEZ, Biocon Park,
  • Plot No. 2 & 3
  • Bengaluru
  • Karnataka
  • 560099
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/27 15:49
End of Day Share Price2021/10/27 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.